The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells

被引:92
作者
Serrano-Marco, L. [1 ,2 ]
Barroso, E. [1 ,2 ]
El Kochairi, I. [3 ]
Palomer, X. [1 ,2 ]
Michalik, L. [3 ]
Wahli, W. [3 ]
Vazquez-Carrera, M. [1 ,2 ]
机构
[1] Univ Barcelona, Pharmacol Unit, Dept Pharmacol & Therapeut Chem, Fac Pharm,Inst Biomed UB IBUB, E-08028 Barcelona, Spain
[2] Inst Salud Carlos III, CIBER Diabet & Enfermedades Metab Asociadas CIBER, Madrid, Spain
[3] Univ Lausanne, Ctr Integrat Genom, Natl Res Ctr Frontiers Genet, Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
AMPK; ERK1/2; IL-6; PPAR beta/delta; SOCS3; STAT3; TUMOR-NECROSIS-FACTOR; SERINE PHOSPHORYLATION; SKELETAL-MUSCLE; FACTOR-ALPHA; CIRCULATING INTERLEUKIN-6; METABOLIC SYNDROME; IN-VIVO; DELTA; OBESITY; EXPRESSION;
D O I
10.1007/s00125-011-2401-4
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
IL-6 induces insulin resistance by activating signal transducer and activator of transcription 3 (STAT3) and upregulating the transcription of its target gene SOCS3. Here we examined whether the peroxisome proliferator-activated receptor (PPAR)beta/delta agonist GW501516 prevented activation of the IL-6-STAT3-suppressor of cytokine signalling 3 (SOCS3) pathway and insulin resistance in human hepatic HepG2 cells. Studies were conducted with human HepG2 cells and livers from mice null for Ppar beta/delta (also known as Ppard) and wild-type mice. GW501516 prevented IL-6-dependent reduction in insulin-stimulated v-akt murine thymoma viral oncogene homologue 1 (AKT) phosphorylation and in IRS-1 and IRS-2 protein levels. In addition, treatment with this drug abolished IL-6-induced STAT3 phosphorylation of Tyr(705) and Ser(727) and prevented the increase in SOCS3 caused by this cytokine. Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Ppar beta/delta-null mice showed increased Tyr(705)- and Ser(727)-STAT3 as well as phospho-ERK1/2 levels. Furthermore, drug treatment prevented the IL-6-dependent reduction in phosphorylated AMP-activated protein kinase (AMPK), a kinase reported to inhibit STAT3 phosphorylation on Tyr(705). In agreement with the recovery in phospho-AMPK levels observed following GW501516 treatment, this drug increased the AMP/ATP ratio and decreased the ATP/ADP ratio. Overall, our findings show that the PPAR beta/delta activator GW501516 prevents IL-6-induced STAT3 activation by inhibiting ERK1/2 phosphorylation and preventing the reduction in phospho-AMPK levels. These effects of GW501516 may contribute to the prevention of cytokine-induced insulin resistance in hepatic cells.
引用
收藏
页码:743 / 751
页数:9
相关论文
共 47 条
[1]
Auwerx J, 1999, CELL, V97, P161
[2]
PPARδ:: a dagger in the heart of the metabolic syndrome [J].
Barish, GD ;
Narkar, VA ;
Evans, RM .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (03) :590-597
[3]
The PPARβ/δ Activator GW501516 Prevents the Down-Regulation of AMPK Caused by a High-Fat Diet in Liver and Amplifies the PGC-1α-Lipin 1-PPARα Pathway Leading to Increased Fatty Acid Oxidation [J].
Barroso, Emma ;
Rodriguez-Calvo, Ricardo ;
Serrano-Marco, Lucia ;
Astudillo, Alma M. ;
Balsinde, Jesus ;
Palomer, Xavier ;
Vazquez-Carrera, Manuel .
ENDOCRINOLOGY, 2011, 152 (05) :1848-1859
[4]
Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro [J].
Bastard, JP ;
Maachi, M ;
Van Nhieu, JT ;
Jardel, C ;
Bruckert, E ;
Grimaldi, A ;
Robert, JJ ;
Capeau, J ;
Hainque, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (05) :2084-2089
[5]
BESEDOVSKY HO, 1990, ANN NY ACAD SCI, V594, P214
[6]
The role of STATs in transcriptional control and their impact on cellular function [J].
Bromberg, J ;
Darnell, JE .
ONCOGENE, 2000, 19 (21) :2468-2473
[7]
Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes:: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness [J].
Carey, AL ;
Bruce, CR ;
Sacchetti, M ;
Anderson, MJ ;
Olsen, DB ;
Saltin, B ;
Hawley, JA ;
Febbraio, MA .
DIABETOLOGIA, 2004, 47 (06) :1029-1037
[8]
Interleukin-6 and insulin sensitivity: friend or foe? [J].
Carey, AL ;
Febbraio, MA .
DIABETOLOGIA, 2004, 47 (07) :1135-1142
[9]
Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-γ coactivator 1α in skeletal muscle cells involves MEK1/2 and nuclear factor-κB activation [J].
Coll, Teresa ;
Jove, Mireia ;
Rodriguez-Calvo, Ricardo ;
Eyre, Elena ;
Palomer, Xavier ;
Sanchez, Rosa M. ;
Merlos, Manuel ;
Laguna, Juan Carlos ;
Vazquez-Carrera, Manuel .
DIABETES, 2006, 55 (10) :2779-2787
[10]
Emerging roles of PPARs in inflammation and immunity [J].
Daynes, RA ;
Jones, DC .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (10) :748-759